The role of histone deacetylase inhibitors in metastatic breast cancer

Bruna Zucchetti; Andrea Kazumi Shimada; Artur Katz; Giuseppe Curigliano

doi:10.1016/j.breast.2018.12.001

The role of histone deacetylase inhibitors in metastatic breast cancer

Bruna Zucchetti, Andrea Kazumi Shimada, Artur Katz, Giuseppe Curigliano

Istituto Europeo di Oncologia

Research output: Contribution to journal › Review article › peer-review

Abstract

Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.

Original language	English
Pages (from-to)	130-134
Number of pages	5
Journal	Breast
Volume	43
DOIs	https://doi.org/10.1016/j.breast.2018.12.001
Publication status	Published - Feb 2019

Keywords

Breast cancer
Epigenetic
Histone acetylation

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.breast.2018.12.001

Fingerprint Dive into the research topics of 'The role of histone deacetylase inhibitors in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this

@article{b7160fde07c14c61bc6a2ebe85bb8140,

title = "The role of histone deacetylase inhibitors in metastatic breast cancer",

abstract = "Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.",

keywords = "Breast cancer, Epigenetic, Histone acetylation",

author = "Bruna Zucchetti and Shimada, {Andrea Kazumi} and Artur Katz and Giuseppe Curigliano",

year = "2019",

month = feb,

doi = "10.1016/j.breast.2018.12.001",

language = "English",

volume = "43",

pages = "130--134",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - The role of histone deacetylase inhibitors in metastatic breast cancer

AU - Zucchetti, Bruna

AU - Shimada, Andrea Kazumi

AU - Katz, Artur

AU - Curigliano, Giuseppe

PY - 2019/2

Y1 - 2019/2

N2 - Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.

AB - Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.

KW - Breast cancer

KW - Epigenetic

KW - Histone acetylation

UR - http://www.scopus.com/inward/record.url?scp=85059302641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059302641&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2018.12.001

DO - 10.1016/j.breast.2018.12.001

M3 - Review article

C2 - 30553187

AN - SCOPUS:85059302641

VL - 43

SP - 130

EP - 134

JO - Breast

JF - Breast

SN - 0960-9776

ER -